[go: up one dir, main page]

EP4583860A1 - Inhibiteurs de la voie métabolique de céramide pour surmonter la résistance à l'immunothérapie dans le cancer - Google Patents

Inhibiteurs de la voie métabolique de céramide pour surmonter la résistance à l'immunothérapie dans le cancer

Info

Publication number
EP4583860A1
EP4583860A1 EP23767849.5A EP23767849A EP4583860A1 EP 4583860 A1 EP4583860 A1 EP 4583860A1 EP 23767849 A EP23767849 A EP 23767849A EP 4583860 A1 EP4583860 A1 EP 4583860A1
Authority
EP
European Patent Office
Prior art keywords
ethyl
ceramide
patient
methoxyphenyl
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP23767849.5A
Other languages
German (de)
English (en)
Inventor
Bruno SEGUI
Nicolas Meyer
Thierry Levade
Anne Montfort
Nathalie ANDRIEU-ABADIE
Carine DUFAU
Matthieu GENAIS
Benjamin Jung
Jean-Pierre Delord
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique CNRS
Institut National de la Sante et de la Recherche Medicale INSERM
INSTITUT CLAUDIUS REGAUD
Universite de Toulouse
Original Assignee
Centre National de la Recherche Scientifique CNRS
Institut National de la Sante et de la Recherche Medicale INSERM
INSTITUT CLAUDIUS REGAUD
Universite Toulouse III Paul Sabatier
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre National de la Recherche Scientifique CNRS, Institut National de la Sante et de la Recherche Medicale INSERM, INSTITUT CLAUDIUS REGAUD, Universite Toulouse III Paul Sabatier filed Critical Centre National de la Recherche Scientifique CNRS
Publication of EP4583860A1 publication Critical patent/EP4583860A1/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man

Definitions

  • the present invention relates to a method of overcoming immunotherapy resistance in patient suffering from cancer thereof comprising administering to the patent a therapeutically effective amount of an agent that reduces or prevents the increase in ceramide and glycosylated ceramide levels.
  • the subject suffers from a cancer selected from the group consisting of Acanthoma, Acinic cell carcinoma, Acoustic neuroma, Acral lentiginous melanoma, Acrospiroma, Acute eosinophilic leukemia, Acute lymphoblastic leukemia, Acute megakaryoblastic leukemia, Acute monocytic leukemia, Acute myeloblastic leukemia with maturation, Acute myeloid dendritic cell leukemia, Acute myeloid leukemia, Acute promyelocytic leukemia, Adamantinoma, Adenocarcinoma, Adenoid cystic carcinoma, Adenoma, Adenomatoid odontogenic tumor, Adrenocortical carcinoma, Adult T-cell leukemia, Aggressive NK-cell leukemia, AIDS-Related Cancers, AIDS-related lymphoma, Alveolar soft part sarcoma, Ameloblastic fibroma, Anal cancer
  • melanoma refers to a condition characterized by the growth of a tumor arising from the melanocytic system of the skin and other organs. Most melanocytes occur in the skin, but are also found in the meninges, digestive tract, lymph nodes and eyes. When melanoma occurs in the skin, it is referred to as cutaneous melanoma. Melanoma can also occur in the eyes and is called ocular or intraocular melanoma. Melanoma occurs rarely in the meninges, the digestive tract, lymph nodes or other areas where melanocytes are found. In some embodiments, the melanoma is a metastatic melanoma.
  • BRAF serine-threonine protein kinase B-RAF
  • BRAFV600E a single nucleotide mutation resulting in substitution of valine for glutamic acid
  • the treatment may be administered to a subject having a medical disorder or who ultimately may acquire the disorder, in order to prevent, cure, delay the onset of, reduce the severity of, or ameliorate one or more symptoms of a disorder or recurring disorder, or in order to prolong the survival of a subject beyond that expected in the absence of such treatment.
  • therapeutic regimen is meant the pattern of treatment of an illness, e.g., the pattern of dosing used during therapy.
  • a therapeutic regimen may include an induction regimen and a maintenance regimen.
  • the phrase "induction regimen” or “induction period” refers to a therapeutic regimen (or the portion of a therapeutic regimen) that is used for the initial treatment of a disease.
  • An induction regimen may employ (in part or in whole) a "loading regimen", which may include administering a greater dose of the drug than a physician would employ during a maintenance regimen, administering a drug more frequently than a physician would administer the drug during a maintenance regimen, or both.
  • loading regimen may include administering a greater dose of the drug than a physician would employ during a maintenance regimen, administering a drug more frequently than a physician would administer the drug during a maintenance regimen, or both.
  • the phrase "maintenance regimen” or “maintenance period” refers to a therapeutic regimen (or the portion of a therapeutic regimen) that is used for the maintenance of a patient during treatment of an illness, e.g., to keep the patient in remission for long periods of time (months or years).
  • a maintenance regimen may employ continuous therapy (e.g., administering a drug at a regular interval, e.g., weekly, monthly, yearly, etc.) or intermittent therapy (e.g., interrupted treatment, intermittent treatment, treatment at relapse, or treatment upon achievement of a particular predetermined criteria [e.g., disease manifestation, etc.]).
  • continuous therapy e.g., administering a drug at a regular interval, e.g., weekly, monthly, yearly, etc.
  • intermittent therapy e.g., interrupted treatment, intermittent treatment, treatment at relapse, or treatment upon achievement of a particular predetermined criteria [e.g., disease manifestation, etc.]).
  • immunotherapy has its general meaning in the art and refers to the treatment that consists in administering an immunogenic agent i.e. an agent capable of inducing, enhancing, suppressing or otherwise modifying an immune response.
  • an immunogenic agent i.e. an agent capable of inducing, enhancing, suppressing or otherwise modifying an immune response.
  • immune checkpoint protein has its general meaning in the art and refers to a molecule that is expressed by T cells in that either turn up a signal (stimulatory checkpoint molecules) or turn down a signal (inhibitory checkpoint molecules).
  • Immune checkpoint molecules are recognized in the art to constitute immune checkpoint pathways similar to the CTLA-4 and PD-1 dependent pathways (see e.g. Pardoll, 2012. Nature Rev Cancer 12:252-264; Mellman et al. , 2011. Nature 480:480- 489).
  • inhibitory checkpoint molecules include A2AR, B7-H3, B7-H4, BTLA, CTLA-4, CD277, IDO, KIR, PD- 1, LAG-3, TIM-3 and VISTA.
  • Inhibition includes reduction of function and full blockade.
  • Preferred immune checkpoint inhibitors are antibodies that specifically recognize immune checkpoint proteins. A number of immune checkpoint inhibitors are known and in analogy of these known immune checkpoint protein inhibitors, alternative immune checkpoint inhibitors may be developed in the (near) future.
  • the immune checkpoint inhibitors include peptides, antibodies, nucleic acid molecules and small molecules. Examples of immune checkpoint inhibitor includes PD-1 antagonist, PD-L1 antagonist, PD-L2 antagonist CTLA-4 antagonist, VISTA antagonist, TIM-3 antagonist, LAG-3 antagonist, IDO antagonist, KIR2D antagonist, A2AR antagonist, B7-H3 antagonist, B7-H4 antagonist, and BTLA antagonist.
  • the anti-PD-1 antibody is selected from the group consisting of MDX-1106 (also known as Nivolumab, MDX-1106-04, ONO-4538, BMS-936558, and Opdivo®), Merck 3475 (also known as Pembrolizumab, MK-3475, Lambrolizumab, Keytruda®, and SCH-900475), and CT-011 (also known as Pidilizumab, hBAT, and hBAT-1).
  • the PD-1 binding antagonist is AMP-224 (also known as B7-DCIg).
  • Merck 3745 also known as MK-3475 or SCH-900475, is an anti-PD-1 antibody described in U.S. Pat. No. 8,345,509 and W02009/114335.
  • CT-011 Panizilumab
  • AMP-224 also known as B7-DCIg, is a PD-L2-Fc fusion soluble receptor described in W02010/027827 and WO2011/066342.
  • Atezolimumab is an anti-PD-Ll antibody described in U.S. Pat. No. 8,217,149.
  • Avelumab is an anti-PD-Ll antibody described in US 20140341917.
  • CA-170 is a PD-1 antagonist described in W02015033301 & WO2015033299.
  • Other anti-PD-1 antibodies are disclosed in U.S. Pat. No. 8,609,089, US 2010028330, and/or US 20120114649.
  • the PD-1 inhibitor is an anti-PD-1 antibody chosen from Nivolumab, Pembrolizumab or Pidilizumab.
  • CTLA-4 antibodies are described in U.S. Pat. Nos. 5,811,097; 5,855,887; 6,051,227; and 6,984,720; in PCT Publication Nos. WO 01/14424 and WO 00/37504; and in U.S. Publication Nos. 2002/0039581 and 2002/086014.
  • Other anti-CTLA-4 antibodies that can be used in a method of the present invention include, for example, those disclosed in: WO 98/42752; U.S. Pat.
  • a preferred clinical CTLA-4 antibody is human monoclonal antibody (also referred to as MDX-010 and Ipilimumab with CAS No.
  • CTLA-4 antagonist antibodies
  • Tremelimumab CP-675,206
  • Ipilimumab Ipilimumab
  • the immunotherapy consists in administering to the patient a combination of a CTLA-4 antagonist and a PD-1 antagonist.
  • the responders have an objective response and therefore the term does not encompass patients having a stabilized cancer such that the disease is not progressing after immunotherapy.
  • a “non-responder” or “refractory patient” includes patients for whom the cancer does not show reduction or improvement after immunotherapy.
  • the term “non responder” also includes patients having a stabilized cancer.
  • the characterization of the patient as a responder or non-responder can be performed by reference to a standard or a training set.
  • the standard may be the profile of a patient who is known to be a responder or non-responder or alternatively may be a numerical value.
  • Such predetermined standards may be provided in any suitable form, such as a printed list or diagram, computer software program, or other media.
  • the physician could take the decision to administer the agent that reduces or prevents the increase in ceramide levels. More particularly, the method of the present invention is particularly suitable for preventing tumor escape in a patient treated with immunotherapy.
  • tumor escape refers to any mechanism by which tumors escape the host's immune system.
  • the immunotherapy resistance (or tumor escape) is induced by TNF- alpha. More particularly, the immunotherapy resistance results from the dedifferentiation of the tumor cells that is induced by TNF-alpha.
  • dedifferentiation refers to processes by which a tumor cell become less specialized in phenotype and broader in lineage potential.
  • the method of the present invention comprises administering to the patient a therapeutically effective combination of the agent that reduces or prevents the increase in ceramide levels with a TNFa blocking agent.
  • TNFa blocking agent or "TBA”
  • TBA a biological agent which is capable of neutralizing the effects of TNFa.
  • Said agent is a preferentially a protein such as a soluble TNFa receptor, e.g. Pegsunercept, or an antibody.
  • the TBA is a monoclonal antibody having specificity for TNFa or for TNFa receptor.
  • the TBA is selected in the group consisting of Etanercept (Enbrel®), Infliximab (Remicade®), Adalimumab (Humira®), Certolizumab pegol (Cimzia®), and golimumab (Simponi®).
  • TNF-receptor based proteins have also been developed (e.g. etanercept, a recombinant fusion protein consisting of two extracellular parts of soluble TNFa receptor 2 (p75) joined by the Fc fragment of a human IgGl molecule).
  • etanercept a recombinant fusion protein consisting of two extracellular parts of soluble TNFa receptor 2 (p75) joined by the Fc fragment of a human IgGl molecule.
  • a pegylated soluble TNF type 1 receptor can also be used as a TNF blocking agent.
  • thalidomide has been demonstrated to be a potent inhibitor of TNF production.
  • TNFa blocking agents thus further include phosphodiesterase 4 (IV) inhibitor thalidomide analogues and other phosphodiesterase IV inhibitors.
  • Ceramide levels may be determined through any number of techniques known to those skilled in the art including but not limited to thin layer chromatography, high-pressure liquid chromatography, mass spectrometry, immunochemical based assays and enzyme based assays, including those using ceramide kinase or diacylglycerol kinase as described by Bektas etal. (Analytical Biochemistry 320 (2003) 259-265), and Modrak (Methods in Molecular Medicine, vol. Ill :Vol 2: In Vivo Models, Imaging and Molecular Regulators., Ed. Blumenthal. Humana Press Inc., NJ), and herby incorporated by reference.
  • the agent of the present invention decreases the level of glycosphingolipids.
  • the agents typically include any chemical compound, or bioactive molecule derived from any living organism, including agents derived from animal, plant, fungus or bacteria, including but not limited to amino acids, polypeptides, carbohydrates, oligonucleotides, or combinations thereof, which directly or indirectly inhibit ceramide synthesis, or the synthesis of ceramide metabolic enzymes.
  • the most well-known examples are inhibitors which target the enzymes of the de novo synthesis and sphingomyelinase pathways.
  • the ceramide de novo pathway compromises a series of enzymes leading to ceramide from the starting components serine and palmitoyl CoA.
  • the agent that inhibits ceramide synthesis is selected from the group consisting of serine palmitoyltransferase inhibitors, ceramide synthase inhibitors, dihydroceramide desaturase inhibitors, sphingomyelinase inhibitors, acid sphingomyelinase inhibitors, neutral sphingomyelinase inhibitors, alkaline sphingomyelinase inhibitors physiological sphingomyelinase inhibitors, sphingomyelin analogs, scyphostatin, scyphostatin analogs, and L-camitine.
  • inhibitors of ceramide synthesis disclosed herein are non-exhaustive.
  • derivatives, analogs i.e. compound having a structure similar to that of another compound but differing from certain components such as, as example, one atom, a functional group or substructures
  • fragments of these inhibitors would similarly be inhibitory.
  • agents that decrease ceramide pathway metabolic enzymes, or increase ceramide catabolic enzymes including but not limited to agents, which modify, or regulate transcriptional or translational activity or which otherwise degrade, inactivate, or protect theses enzymes.
  • the term "therapeutically effective amount” is meant a sufficient amount of the agent that reduces or prevents the increase in ceramide levels for treating or reducing the symptoms at reasonable benefit/risk ratio applicable to any medical treatment. It will be understood that the total daily usage of the compounds and compositions of the present invention will be decided by the attending physician within the scope of sound medical judgment.
  • the specific therapeutically effective dose level for any particular subject will depend upon a variety of factors including the disorder being treated and the severity of the disorder; activity of the specific compound employed; the specific composition employed, the age, body weight, general health, sex and diet of the subject; the time of administration, route of administration, and rate of excretion of the specific compound employed; the duration of the treatment; drugs used in combination with the active ingredients; and like factors well known in the medical arts.
  • the daily dosage of the products may be varied over a wide range from 0.01 to 1,000 mg per adult per day.
  • the compositions contain 0.01, 0.05, 0.1, 0.5, 1.0, 2.5, 5.0, 10.0, 15.0, 25.0, 50.0, 100, 250 and 500 mg of the active ingredient for the symptomatic adjustment of the dosage to the subject to be treated.
  • a medicament typically contains from about 0.01 mg to about 500 mg of the active ingredient, typically from 1 mg to about 100 mg of the active ingredient.
  • An effective amount of the drug is ordinarily supplied at a dosage level from 0.0002 mg/kg to about 20 mg/kg of body weight per day, especially from about 0.001 mg/kg to 7 mg/kg of body weight per day.
  • the agent that reduces or prevents the increase in ceramide levels is combined with pharmaceutically acceptable excipients, and optionally sustained-release matrices, such as biodegradable polymers, to form pharmaceutical compositions.
  • the carrier can also be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol, and the like), suitable mixtures thereof, and vegetables oils.
  • the proper fluidity can be maintained, for example, by the use of a coating, such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants.
  • the prevention of the action of microorganisms can be brought about by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, thimerosal, and the like.
  • Suitable unit administration forms comprise oral-route forms such as tablets, gel capsules, powders, granules and oral suspensions or solutions, sublingual and buccal administration forms, aerosols, implants, subcutaneous, transdermal, topical, intraperitoneal, intramuscular, intravenous, subdermal, transdermal, intrathecal and intranasal administration forms and rectal administration forms.
  • a further object of the present invention relates to a method of determining whether a patient suffering from a cancer will achieve a response with immunotherapy comprising determining the level of at least one ceramide metabolite in a blood sample from the patient wherein said level correlates with the response of the patient to immunotherapy.
  • low refers to a measure that is less than normal, less than a standard such as a predetermined reference value or a subgroup measure that is relatively less than another subgroup measure.
  • low ceramide derivative means a measure of the ceramide derivative that is less than a normal the ceramide derivative measure in a particular set of patient samples. A normal the ceramide derivative measure may be determined according to any method available to one skilled in the art.
  • Low ceramide derivative may also mean a measure that is less than a predetermined reference value, such as a predetermined cutoff value.
  • Low ceramide derivative may also mean a measure wherein a low ceramide derivative subgroup is relatively lower than another subgroup.
  • two distinct patient subgroups can be created by dividing samples around a mathematically determined point, such as, without limitation, a median, thus creating a group whose measure is low (i.e., less than the median) with respect to another group whose measure is high (i.e., greater than the median).
  • a mathematically determined point such as, without limitation, a median
  • the term “high” refers to a measure that is greater than normal, greater than a standard such as a predetermined reference value or a subgroup measure or that is relatively greater than another subgroup measure.
  • high ceramide derivative refers to a measure of the ceramide derivative that is greater than a normal the ceramide derivative measure.
  • a normal ceramide derivative measure may be determined according to any method available to one skilled in the art.
  • High ceramide derivative may also refer to a measure that is equal to or greater than a predetermined reference value, such as a predetermined cutoff.
  • High ceramide derivative may also refer to a measure of the ceramide derivative wherein a high ceramide derivative subgroup has relatively greater levels of the ceramide derivative than another subgroup.
  • two distinct patient subgroups can be created by dividing samples around a mathematically determined point, such as, without limitation, a median, thus creating a subgroup whose measure is high (i.e., higher than the median) and another subgroup whose measure is low.
  • a “high” level may comprise a range of level that is very high and a range of level that is “moderately high” where moderately high is a level that is greater than normal, but less than “very high”.
  • ROC curve is receiver operator characteristic curve, which is also known as receiver operation characteristic curve. It is mainly used for clinical biochemical diagnostic tests. ROC curve is a comprehensive indicator that reflects the continuous variables of true positive rate (sensitivity) and false positive rate (1-specificity). It reveals the relationship between sensitivity and specificity with the image composition method. A series of different cut-off values (thresholds or critical values, boundary values between normal and abnormal results of diagnostic test) are set as continuous variables to calculate a series of sensitivity and specificity values.
  • sensitivity is used as the vertical coordinate and specificity is used as the horizontal coordinate to draw a curve.
  • AUC area under the curve
  • the point closest to the far upper left of the coordinate diagram is a critical point having both high sensitivity and high specificity values.
  • the AUC value of the ROC curve is between 1.0 and 0.5. When AUC>0.5, the diagnostic result gets better and better as AUC approaches 1. When AUC is between 0.5 and 0.7, the accuracy is low. When AUC is between 0.7 and 0.9, the accuracy is moderate. When AUC is higher than 0.9, the accuracy is high.
  • This algorithmic method is preferably done with a computer.
  • ROC curve such as: MedCalc 9.2.0.1 medical statistical software, SPSS 9.0, ROCPOWER.SAS, DESIGNROC.FOR, MULTIREADER POWER. SAS, CREATE-ROC.SAS, GB STAT VIO.O (Dynamic Microsystems, Inc. Silver Spring, Md., USA), etc.
  • the method comprises the steps of i) determining the level of at least one ceramide metabolite in the blood sample, ii) comparing the level determined at step i) with a predetermined reference level wherein differential between the determined level and the predetermined reference level indicates whether the patient will achieve or not a response to immunotherapy.
  • the level of the ceramide derivative when the level of the ceramide derivative is lower that its predetermined reference level, it is concluded that the patient will achieve a response.
  • the predetermined reference level is the level of the ceramide derived determined before the administration of the immunotherapy (“baseline value”). In some embodiments, the level of the ceramide derivative is determined along the therapy, wherein an increase of the level of ceramide derivative indicates that the patient will not achieve a response, and conversely a decrease of the level of the ceramide derivative indicates that the patient will achieve a response.
  • FIGURES are a diagrammatic representation of FIGURES.
  • TNF modulates the expression of genes involved in ceramide metabolism regulation.
  • Gene Ontology pathway analysis from RNA Seq data generated in the human melanoma cell line WM35 incubated with 50 ng/mL TNF for 24h as compared to untreated cells (n 4).
  • TNF increases the levels of various ceramide metabolites.
  • the human melanoma cell line (WM35) was incubated with or without 50 ng/mL TNF for 48h. Intracellular ceramide metabolites were quantified by mass spectrometry. Ceramide metabolites, which significantly increased upon TNF treatment, are indicated (SM: sphingomyelin; dhSM: dihydrosphingomyelin; Cer: ceramide; dhCer: dihydroceramide; HexCer: monhexosylceramide; CDH: dihexosylceramide). Numbers of carbons and double bonds on the fatty acid linked to the sphingosine backbone are indicated, respectively.
  • FIG. 3 Exogenous ceramides trigger melanoma cell dedifferentiation.
  • the WM35 melanoma cell line was incubated with (C2-Cer) or without (NT) cell permeant ceramides (ceramides C2:0) for 24h.
  • Melan-a expression was evaluated by flow cytometry. (MFI: Median Fluorescent Intensity).
  • FIG. 4 Fumonisin Bl impairs TNF-induced melanoma cell dedifferentiation.
  • WM35 melanoma cell line was incubated with 5 pM fumonisin Bl (FBI) and 50 ng/mL TNF for 72 hours. Melan-a expression was evaluated by flow cytometry.
  • A Sensitivity and specificity of this score to predict the clinical response was determined.
  • TNF triggered the increase of various ceramide derivatives as evaluated by mass spectrometry, including some (dihydro)sphingomyelins, (dihydro)ceramides, monohexosylceramides and dihexosylceramides ( Figure 2).

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Le mélanome cutané avancé peut être traité par immunothérapie ciblant des points de contrôle immunitaire tels que PD-1 et CTL-A4. Cependant, 50 % des patients ne répondent pas du fait d'un mécanisme de résistance primaire ou acquis. Ainsi, de nouvelles cibles pour l'adressage du traitement de ladite résistance sont très nécessaires. Les inventeurs montrent que le TNF (facteur de nécrose tumorale) et les altérations du métabolisme du céramide dans les cellules de mélanome contribuent à la progression du mélanome et à la résistance aux immunothérapies. En particulier, les inventeurs démontrent que le TNF est un modulateur puissant du métabolisme du céramide et des changements du métabolisme du céramide médié par le TNF contribuent à divers processus biologiques tels que la prolifération cellulaire, la mort cellulaire et la différenciation cellulaire. Parmi les processus biologiques par lesquels le TNF déclenche l'échappement immunitaire du mélanome et la résistance aux immunothérapies, le TNF déclenche un processus de dédifférenciation de cellules de mélanome associées à la réduction de l'expression de l'antigène mélanocytique et de la transition épithéliale à mésenchymateuse. Enfin, les inventeurs montrent que le motif glycosphingolipide dans le plasma peut prédire le résultat clinique d'un mélanome avancé traité avec de l'ipilimumab et du nivolumab. Par conséquent, les métabolites de céramide et les enzymes de métabolisation peuvent être de nouvelles cibles thérapeutiques et/ou biomarqueurs chez les patients atteints de mélanome avancés traités avec des immunothérapies.
EP23767849.5A 2022-09-06 2023-09-05 Inhibiteurs de la voie métabolique de céramide pour surmonter la résistance à l'immunothérapie dans le cancer Pending EP4583860A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP22306318 2022-09-06
PCT/EP2023/074343 WO2024052356A1 (fr) 2022-09-06 2023-09-05 Inhibiteurs de la voie métabolique de céramide pour surmonter la résistance à l'immunothérapie dans le cancer

Publications (1)

Publication Number Publication Date
EP4583860A1 true EP4583860A1 (fr) 2025-07-16

Family

ID=83438233

Family Applications (1)

Application Number Title Priority Date Filing Date
EP23767849.5A Pending EP4583860A1 (fr) 2022-09-06 2023-09-05 Inhibiteurs de la voie métabolique de céramide pour surmonter la résistance à l'immunothérapie dans le cancer

Country Status (2)

Country Link
EP (1) EP4583860A1 (fr)
WO (1) WO2024052356A1 (fr)

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5851795A (en) 1991-06-27 1998-12-22 Bristol-Myers Squibb Company Soluble CTLA4 molecules and uses thereof
US5855887A (en) 1995-07-25 1999-01-05 The Regents Of The University Of California Blockade of lymphocyte down-regulation associated with CTLA-4 signaling
US5811097A (en) 1995-07-25 1998-09-22 The Regents Of The University Of California Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US6051227A (en) 1995-07-25 2000-04-18 The Regents Of The University Of California, Office Of Technology Transfer Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
WO1998042752A1 (fr) 1997-03-21 1998-10-01 Brigham And Women's Hospital Inc. Peptides immunotherapeutiques se liant a ctla-4
US7109003B2 (en) 1998-12-23 2006-09-19 Abgenix, Inc. Methods for expressing and recovering human monoclonal antibodies to CTLA-4
WO2000037504A2 (fr) 1998-12-23 2000-06-29 Pfizer Inc. Anticorps monoclonaux humains diriges contre l'antigene ctla-4
EE05627B1 (et) 1998-12-23 2013-02-15 Pfizer Inc. CTLA-4 vastased inimese monoklonaalsed antikehad
EP1212422B1 (fr) 1999-08-24 2007-02-21 Medarex, Inc. Anticorps contre l'antigene ctla-4 humain et utilisation
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
JP2003520828A (ja) 2000-01-27 2003-07-08 ジェネティクス インスティテュート，エルエルシー Ｃｔｌａ４（ｃｄ１５２）に対する抗体、これを含む結合体、およびその使用
WO2004035607A2 (fr) 2002-10-17 2004-04-29 Genmab A/S Anticorps monoclonaux humains anti-cd20
CN101899114A (zh) 2002-12-23 2010-12-01 惠氏公司 抗pd-1抗体及其用途
CN109485727A (zh) 2005-05-09 2019-03-19 小野药品工业株式会社 程序性死亡-1(pd-1)的人单克隆抗体及使用抗pd-1抗体来治疗癌症的方法
KR101411165B1 (ko) 2005-07-01 2014-06-25 메다렉스, 엘.엘.시. 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날항체
PL2242773T3 (pl) 2008-02-11 2017-11-30 Cure Tech Ltd. Przeciwciała monoklonalne do leczenia nowotworu
EP2262837A4 (fr) 2008-03-12 2011-04-06 Merck Sharp & Dohme Protéines de liaison avec pd-1
CA2735006A1 (fr) 2008-08-25 2010-03-11 Amplimmune, Inc. Antagonistes de pd-1 et leurs procedes d'utilisation
EP2927240A1 (fr) 2008-08-25 2015-10-07 Amplimmune, Inc. Compositions d'antagonistes pd-1 et procédés d'utilisation
WO2010077634A1 (fr) 2008-12-09 2010-07-08 Genentech, Inc. Anticorps anti-pd-l1 et leur utilisation pour améliorer la fonction des lymphocytes t
US8647623B2 (en) 2009-04-10 2014-02-11 Kyowa Hakko Kirin Co., Ltd Method for treatment of blood tumor using anti-TIM-3 antibody
US8289808B2 (en) 2009-04-16 2012-10-16 Chevron U.S.A., Inc. System and method to estimate compressional to shear velocity (VP/VS) ratio in a region remote from a borehole
NZ599405A (en) 2009-11-24 2014-09-26 Medimmune Ltd Targeted binding agents against b7-h1
US20130017199A1 (en) 2009-11-24 2013-01-17 AMPLIMMUNE ,Inc. a corporation Simultaneous inhibition of pd-l1/pd-l2
HUE040213T2 (hu) 2010-06-11 2019-02-28 Kyowa Hakko Kirin Co Ltd Anti-TIM antitest
US8841418B2 (en) 2011-07-01 2014-09-23 Cellerant Therapeutics, Inc. Antibodies that specifically bind to TIM3
EP2785375B1 (fr) 2011-11-28 2020-07-22 Merck Patent GmbH Anticorps anti-pd-l1 et leur utilisation
DK3363790T3 (da) 2013-09-06 2020-04-27 Aurigene Discovery Tech Ltd 1,2,4-oxadiazolderivater som immunmodulatorer
CU24345B1 (es) 2013-09-06 2018-05-08 Aurigene Discovery Tech Ltd Derivados de 1,3,4-oxadiazol y 1,3,4-tiadiazol como inmunomoduladores
WO2016145427A1 (fr) * 2015-03-12 2016-09-15 Health Research, Inc. Combinaison d'antagonistes de récepteur ss-adrénergique et d'inhibiteurs de point de contrôle pour améliorer l'efficacité contre le cancer
US11078277B2 (en) * 2016-02-02 2021-08-03 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and pharmaceutical compositions for enhancing CD8+ T cell-dependent immune responses in subjects suffering from cancer

Also Published As

Publication number Publication date
WO2024052356A1 (fr) 2024-03-14

Similar Documents

Publication Publication Date Title
Stolina et al. RANKL inhibition by osteoprotegerin prevents bone loss without affecting local or systemic inflammation parameters in two rat arthritis models: comparison with anti-TNFα or anti-IL-1 therapies
Condino et al. Involvement of β3-adrenoceptors in the inhibitory control of cholinergic activity in human bladder: Direct evidence by [3H]-acetylcholine release experiments in the isolated detrusor
CA3197716A1 (fr) Procede de traitement de la depression par modulation immunitaire
US20210145825A1 (en) Use of opioid antagonists
JP6180494B2 (ja) 新規ヒアルロン酸分解促進因子及びその阻害剤
JP7564347B2 (ja) 多発性硬化症を治療するためのｌｏｕ０６４
US11278524B2 (en) Formulations and methods for the treatment of cancers
WO2002100408A2 (fr) Traitement de la douleur par le ciblage des canaux dependant des nucleotides cycliques actives par hyperpolarisation
AU2017305502A1 (en) Combination of glucagon receptor antagonists and PI3K pathway inhibitors for the treatment of cancer
WO2023107721A1 (fr) Méthodes de traitement de maladies à l'aide d'inhibiteurs de malt1
CN109069467B (zh) 肌生成抑制蛋白拮抗剂的用途、含有它们的组合及其用途
JP2024528705A (ja) がんのための治療としてのクレアチン輸送を阻害するための組成物及び方法
CN115135324A (zh) 通过靶向冷肿瘤治疗癌症的方法
CA2900413A1 (fr) Methode de traitement de l'obesite
KR20190061030A (ko) Mek 억제제, pd-1 축 억제제 및 탁산을 사용한 조합 요법
RU2440142C1 (ru) Антитело, останавливающее или замедляющее рост опухоли (варианты), способ подавления роста опухоли, способ диагностики злокачественных образований
EP4583860A1 (fr) Inhibiteurs de la voie métabolique de céramide pour surmonter la résistance à l'immunothérapie dans le cancer
EP2678360A1 (fr) Méthodes pour traiter et diagnostiquer une maladie
US20210393740A1 (en) Ptprs and proteoglycans in rheumatoid arthritis
Yamaguchi et al. Substance P receptor in U373 MG human astrocytoma cells activates mitogen-activated protein kinases ERK1/2 through Src
JP2025536290A (ja) Ｗｎｔ経路腫瘍抑制因子に突然変異を有する癌の治療
WO2016089888A1 (fr) Anticorps anti-pcsk17 et leurs utilisations
TWI775333B (zh) 治療癌症之方法
Zhu et al. The Pathogenesis of Nephrotic Syndrome: A Perspective from B Cells
Ağbuga et al. Disease and treatment-related comorbidities in rheumatoid arthritis

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: UNKNOWN

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20250305

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)